Bradley Merrill Thompson, Strategic Advisor with EBG Advisors and Member of the Firm in the Health Care & Life Sciences practice at Epstein Becker Green, was quoted in Seeking Alpha, in “Use This App and Call Me in the Morning: The Promise of Prescription Digital Therapeutics,” by Jonathan Block. (Read the full version – subscription required.)
Following is an excerpt:
When it comes to treating diseases, some doctors are looking beyond traditional medicines as therapies.
A growing number of health care professionals are recognizing the value of prescription digital therapeutics (PDTs), a type of evidence-based software program that provides behavioral therapy or other type of therapeutic intervention.
Digital therapeutics can be used on their own or as a complement to other treatments. …
Despite the promise of PDTs, there are a couple of impediments that may get in the way of greater adoption.
The first, as Epstein Becker & Green attorney Bradley Merrill Thompson points out, is limiting who can order PDTs. Allowing prescribing of PDTs to health care practitioners beyond physicians would especially benefit mental health PDTs, he says.
